tumor-infiltrating lymphocytes + aldesleukin

Combination of **autologous tumor-infiltrating lymphocytes (TILs)** expanded ex vivo and **aldesleukin** (recombinant human interleukin-2, rhIL-2), used for adoptive cell therapy in oncology, predominantly in metastatic melanoma and other solid tumors. TILs are harvested from the patient's tumor tissue, expanded in the lab with aldesleukin to boost cytotoxic T cell numbers, and infused back after patient lymphodepletion; aldesleukin is then administered systemically to enhance T cell activation and persistence in vivo. This strategy leverages the innate tumor-targeting capability of TILs and the immunostimulatory effects of aldesleukin, aiming to induce durable tumor responses. Developed from protocols at the National Cancer Institute and further refined in academia and by emerging cell therapy biotech developers.

Other names

TIL + aldesleukinTIL-ACT + IL-2